A recent SEC enforcement action against Cassava Sciences over misleading statements made to the FDA about clinical trial (CT) results highlights the importance of life sciences companies exercising care in how they disclose FDA-related information to investors. Lara Mehraban explains.
The post SEC Interest in FDA-Related Disclosures by Life Sciences Companies Highlighted appeared first on GoodLifeSci.